Project Details
Description
ABSTRACT
In 2020, an estimated 77,240 people in the US will be diagnosed with non-Hodgkin lymphoma (NHL), and 19,940
will die from this cancer. NHL incidence rates increased over the last half of the 20th century and only recently
stabilized. In parallel, NHL survival rates began improving in the mid-1990s with the advent of improved treatment
strategies, leading to the current 5-year survival rate of 74%. These trends have led to a growth in the number
of NHL survivors, estimated at over 757,000 in 2019. To address the unmet health needs of this patient
population, we established the Lymphoma Epidemiology of Outcomes (LEO) cohort study, which by June 2020
will have enrolled over 13,000 NHL patients and have
Status | Active |
---|---|
Effective start/end date | 6/23/15 → 3/31/25 |
Funding
- National Cancer Institute: $1,938,064.00
- National Cancer Institute: $1,876,237.00
- National Cancer Institute: $2,248,270.00
- National Cancer Institute: $2,251,244.00
- National Cancer Institute: $195,572.00
- National Cancer Institute: $20,848.00
- National Cancer Institute: $14,960.00
- National Cancer Institute: $45,332.00
- National Cancer Institute: $1,938,063.00
Fingerprint
Explore the research topics touched on by this project. These labels are generated based on the underlying awards/grants. Together they form a unique fingerprint.